Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.33 |
| ▸ | BPTF | Q12830 | 1/20 | 0.33 |
| ▸ | TPSAB1 | Q15661 | 2/20 | 0.32 |
| ▸ | ABAT | P80404 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.30 |
| ▸ | RORC | P51449 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19738806 | 0.78 | LOXL2 (0.36) | LOXL2HRH3BPTFTPSAB1ABAT | |
| SCHEMBL20346738 | 0.74 | LOXL2 (0.39) | LOXL2HRH3L3MBTL3ABAT | |
| SCHEMBL20979942 | 0.73 | HRH3 (0.52) | HRH3 | |
| SCHEMBL7368542 | 0.73 | ABAT (0.41) | LOXL2HRH3TPSAB1ABATRORC | |
| SCHEMBL22918664 | 0.72 | KLKB1 (0.41) | LOXL2HRH3TPSAB1ABAT | |
| SCHEMBL20345578 | 0.71 | LOXL2 (0.36) | LOXL2HRH3L3MBTL3ABATRORC | |
| SCHEMBL20979915 | 0.70 | LOXL2 (0.35) | LOXL2HRH3ABAT | |
| SCHEMBL18357596 | 0.70 | LOXL2 (0.35) | LOXL2HRH3L3MBTL3ABAT | |
| SCHEMBL22914811 | 0.70 | GFER (0.43) | LOXL2RORC | |
| SCHEMBL12294725 | 0.69 | HRH3 (0.48) | LOXL2HRH3ABAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11179396-B2 | Heterocyclic compounds as antibacterials | JANSSEN SCIENCES IRELAND UC (IE) | 2021-11-23 | — | — | US | disclosed |
| US-20190134046-A1 | HETEROCYCLIC COMPOUNDS AS ANTIBACTERIALS | Janssen Sciences Ireland Unlimited Company (IE) | 2019-05-09 | — | — | US | disclosed |
| WO-2017216281-A1 | HETEROCYCLIC COMPOUNDS AS ANTIBACTERIALS | JANSSEN SCIENCES IRELAND UC (IE) | 2017-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11179396-B2 | Heterocyclic compounds as antibacterials | SQOR, NQO1, NDUFS3 | LOXL2 3752/4885HRH3 1196/4885L3MBTL3 1755/4885 |
| US-20190134046-A1 | HETEROCYCLIC COMPOUNDS AS ANTIBACTERIALS | SQOR, NQO1, NDUFS3 | LOXL2 3752/4885HRH3 1196/4885L3MBTL3 1755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.